![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Outlook Reports Bevacizumab Trial Delays
Outlook Reports Bevacizumab Trial Delays
Outlook Therapeutics reported enrollment delays for a clinical trial of Lytenava (bevacizumab-vikg), its investigational formulation of bevacizumab for use in retinal treatments.
The NORSE 2 trial is continuing to screen and treat patients but is subject to additional COVID-19 safety protocols that have caused some sites to temporarily shut down and enrollment to slow.
Upcoming Events
-
18Jul
-
21Oct